Business
MDxHealth Reports Q1-2025 Results
Year-over-year Q1 revenues increase by 22% to $24.3 million71% year-over-year improvement in adjusted EBITDA in first quarterConference call with Q&A today at 4:30 PM ET / 22:30 CET IRVINE, CA, and HERSTAL, BELGIUM – May 14, 2025 (GlobeNewswire) – MDxHealth SA (NASDAQ: MDXH) (the "Company" or "mdxhealth"), a leading precision diagnostics company, today announced its financial results for the first quarter ended March 31, 2025. Michael K. McGarrity, CEO of mdxhealth, commented: “mdxhealth deliver
About this update from Mdxhealth Sa
[{"type":"image","alt":"mdxhealth","displaySize":"","headline":null,"caption":"mdxhealth","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":44,"url":"https://media.zenfs.com/en/globenewswire.com/4984d0922515a173e18d6d7a99b017cc"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/Sf2Nm0vg.EDhfYYAQ2giIg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTYyO2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/4984d0922515a173e18d6d7a99b017cc","width":300,"height":44}},"lazy":false},{"type":"text","content":"Year-over-year Q1 revenues increase by 22% to $24.3 million71% year-over-year improvement in adjusted EBITDA in first quarterConference call with Q&A today at 4:30 PM ET / 22:30 CET","length":187,"tagName":"p"},{"type":"text","content":"IRVINE, CA, and HERSTAL, BELGIUM – May 14, 2025 (GlobeNewswire) – MDxHealth SA (NASDAQ: MDXH) (the "Company" or "mdxhealth"), a leading precision diagnostics company, today announced its financial results for the first quarter ended March 31, 2025.","length":268,"tagName":"p"},{"type":"text","content":"Michael K. McGarrity, CEO of mdxhealth, commented: “mdxhealth delivered a strong first quarter, marked by our 16th consecutive quarter of 20% or greater revenue growth, fueled by continued execution by our team and strong demand for our precision diagnostics. Our expanded test menu continues to gain traction, and our commercial team is successfully increasing penetration in the urology market we serve. Based on the strength of our business and our solid execution, we are reiterating our 2025 revenue guidance of $108-110 million, and expect to reach adjusted EBITDA profitability in the second quarter of 2025.”","length":616,"tagName":"p"},{"type":"text","content":"Key highlights for the first quarter of 2025:","length":45,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Revenue of $24.3 million, an increase of 22% over prior year period","length":67,"tagName":"p"}]},{"val":[{"type":"text","content":"Adjusted EBITDA of ($1.3) million, a 71% improvement over prior year period","length":75,"tagName":"p"}]},{"val":[{"type":"text","content":"Tissue-based (Confirm mdx and GPS) test volume of 12,677, an increase of 41% over prior year period","length":99,"tagName":"p"}]},{"val":[{"type":"text","content":"Liquid-based (Select mdx, Resolve mdx, Germline) test vol...